Prospective study on association of 25-hydroxy vitamin D3 and uterne fibroid

Shobhana Pradhan, Subhalaxmi Dash, Sudhanshu Sekhara Nanda, Subrat Pradhan, Tushar Kar
In: International journal of health sciences · 2022 · pp. 5219–5230 · doi:10.53730/ijhs.v6ns4.10066 · W4286517406
article OA: diamond CC0
🔓 Open OA copy View on OpenAlex View at publisher

Abstract

Objective: To find the association of 25-hydroxy VitaminD3 and uterine fibroid. Study Design:This is a prospective case control study. Setting: The study was conducted at the PG Department of Obstetrics and Gynaecology , S.C.B. Medical College, Cuttack,Odisha, India.Material & Method: One hundred diagnosed cases of uterine fibroid were included as cases. The control group comprised of age matched hundred healthy volunteers. After obtaining the written consent of cases and controls, they were subjected for routine haematological tests and for Serum total 25-hydroxy vitamin D by chemiluminescent immunoassay (CLIA) method. Ultrasound evaluations were performed by TVS and TAS as per on all consenting subjects. All the data collected were entered into the excel spread sheet and the statistical analysis was carried out by using the graph pad prism 8.0. The quantitative data were expressed as mean ± SD. P value < 0.05 was considered to be statistically significant and P value < 0.01 was considered to be highly significant. Conclusion: The mean vitamin D level in cases was 8.6±2.6 ng/ml while in controls it was 19.23±4.3 ng/ml. The levels of vitamin D were significantly less in fibroid patients than in healthy controls (p<0.001).

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (24)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK